COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4+
SponsorUniversity Hospital, Strasbourg, France

About this trial

ALMS and BBS syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus. There are to date no specific treatments available and limited information on the natural history of the diseases. the investigators aim to establish a French cohort for these diseases to improve patient care and assess the effect of actual therapies on quality of life.

The purpose of this study is to establish a cohort of Bardet-Bield syndrome (BBS) and ALström syndrome (ALMS) patients in order to formalize and address questions concerning the in-depth natural clinical and biological history of the disease on the long term for a given patient, establish the impact on the quality of life of various clinical manifestations

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients of both sex

Age minimum*

patients with social protection

by > 18-year old patients

Disqualifiers

Serious active intercurrent pathology that may impact the collected data

Patient under judicial protection

Participation in another interventional clinical trial which includes an exclusion period

Non protected adult with difficulty of comprehension, or inability to understand the delivered information (emergency situation ...).

Trial design

Design model

Single group

Treatments tested in this trial

  • Skin biopsy

    Genetic

    COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure: * risk of pain due to the procedure performed under local anaesthesia * can leave a visible scar (about 2 x 1 cm)

Treatment groups

350 Participants
are divided into 1 treatment group
Group A: Group ALMS et BBSOther 1 intervention

Trial outcomes

Primary outcomes

1

Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS).

renal function, eyes, endocrine, Clinical Examination

Time frame
5 years
2

Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS).

Record of biological results

Time frame
5 years
3

Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS).

Record of Social Life with questionnaire

Time frame
5 years
4

Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS).

Record of treatments (therapy and surgery)

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.